3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS)

3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS)

In pharmacokinetics, the rate and extent to which an active pharmaceutical ingredient is delivered from a dosage form into the systemic circulation dictates its clinical efficacy and safety profile. Biopharmaceutics examines the interrelationship between the physicochemical properties of the drug, the dosage form in which it is presented, and the route of administration.

---

1. Bioavailability ($F$): Definitions and Mathematical Quantification

Bioavailability refers to the rate and extent to which the active moiety is absorbed from a pharmaceutical form and becomes available at the site of physiological action.

+-------------------------------------------------------------------------------------+
|                       PLASMA CONCENTRATION-TIME PROFILE (ORAL)                      |
+-------------------------------------------------------------------------------------+
| Concentration (C)                                                                   |
|      ^                                                                              |
|      |                 *** (Cmax, Tmax)                                             |
|      |              *       *                                                       |
|      |            *           *                                                     |
|      |          *   Absorption  *   Elimination Phase                               |
|      |         *      Phase       *                                                 |
|      |        *                     *                                               |
|      |       *                        *                                             |
|      |      *      [AUC(0 to infinity)] *                                           |
|      |     *                              *                                         |
|      |    *                                 *                                       |
|      +----------------------------------------*------------> Time (t)               |
|           <--- Tmax --->                                                            |
+-------------------------------------------------------------------------------------+

Absolute Bioavailability ($F_{\text{abs}}$)

Absolute bioavailability compares the systemic exposure of an extravascularly administered drug (e.g., oral, subcutaneous, intramuscular, transdermal) to that of an equivalent intravenous (IV) bolus, where bioavailability is defined as $1.0$ ($100%$):

$F_{\text{abs}} = \frac{\text{AUC}_{\text{oral}} \cdot \text{Dose}_{\text{IV}}}{\text{AUC}_{\text{IV}} \cdot \text{Dose}_{\text{oral}}} = \frac{\text{AUC}_{\text{oral}} / \text{Dose}_{\text{oral}}}{\text{AUC}_{\text{IV}} / \text{Dose}_{\text{IV}}}$

Physiologically, absolute oral bioavailability is the product of three distinct anatomical fractions:

$F = f_a \cdot (1 - E_g) \cdot (1 - E_h)$

Where:

• $f_a$ is the fraction of drug absorbed across the apical membrane of the intestinal enterocytes.
• $E_g$ is the gut-wall extraction ratio (gut first-pass metabolism by CYP3A4/5, UGTs, or apical P-gp efflux).
• $E_h$ is the hepatic extraction ratio (first-pass clearance by hepatic enzymes and biliary excretion).

Relative Bioavailability ($F_{\text{rel}}$)

Relative bioavailability compares the systemic exposure of two different formulations, salt forms, or non-intravenous routes of administration (e.g., generic tablet formulation $T$ versus innovator reference brand $R$, or oral suspension versus tablet):

$F_{\text{rel}} = \frac{\text{AUC}_{\text{Test}} \cdot \text{Dose}_{\text{Reference}}}{\text{AUC}_{\text{Reference}} \cdot \text{Dose}_{\text{Test}}}$

Area Under the Curve (AUC) Calculation

The total extent of systemic drug exposure is calculated using the Linear-Log Trapezoidal Rule from time zero to infinity:

$\text{AUC}_{0-\infty} = \text{AUC}_{0-t_{\text{last}}} + \frac{C_{\text{last}}}{k_e}$

Where $C_{\text{last}}$ is the final quantifiable plasma concentration and $k_e$ is the terminal elimination rate constant.

---

2. Bioequivalence (BE) and Canadian Regulatory Standards

Two pharmaceutical products are considered bioequivalent if they are pharmaceutical equivalents or pharmaceutical alternatives and their bioavailabilities (rate and extent of absorption) after administration in the same molar dose under similar conditions are sufficiently similar that their effects, with respect to both efficacy and safety, will be essentially the same.

Core Pharmacokinetic Metrics Evaluated in BE Studies

1. Extent of Absorption: Measured by the Area Under the Concentration-Time Curve from time zero to the last quantifiable concentration ($\text{AUC}{0-t}$) and extrapolated to infinity ($\text{AUC}{0-\infty}$).
2. Rate of Absorption: Assessed primarily by the Maximum Plasma Concentration ($C_{\text{max}}$) and the Time to Maximum Plasma Concentration ($T_{\text{max}}$).

+-------------------------------------------------------------------------------------+
|             HEALTH CANADA BIOEQUIVALENCE COMPARISON (TEST vs. REFERENCE)            |
+-------------------------------------------------------------------------------------+
|                                                                                     |
|   Standard Drugs:                                                                   |
|   [================= 80.00% ======= 100.00% ======= 125.00% =================]     |
|                      ^-- 90% CI for AUC must fall entirely within --^               |
|                      ^-- Point estimate for Cmax (80.0-125.0%) -----^               |
|                                                                                     |
|   Critical Dose Drugs (Narrow Therapeutic Index):                                   |
|             [======= 90.00% ======= 100.00% ======= 112.00% =======]               |
|                      ^-- 90% CI for BOTH AUC and Cmax within --^                    |
|                                                                                     |
+-------------------------------------------------------------------------------------+

Health Canada Specific Bioequivalence Standards

Health Canada's Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies outlines strict statistical criteria:

• Standard Drug Formulations:

  • AUC: The $90%$ confidence interval for the geometric mean ratio (Test / Reference) of $\text{AUC}_{0-t}$ must fall entirely within the acceptance range of $80.00% \text{ to } 125.00%$ ($0.8000 - 1.2500$).
  • $C_{\text{max}}$: The relative mean ($C_{\text{max}}$ point estimate) of the Test product to Reference product must be between $80.0% \text{ to } 125.0%$ (for some specific drug categories, the $90%$ confidence interval is required).

• Critical Dose Drugs / Narrow Therapeutic Index (NTI) Drugs: Drugs where small differences in dose or concentration may lead to serious therapeutic failures or life-threatening adverse drug reactions (e.g., cyclosporine, digoxin, flecainide, lithium, phenytoin, tacrolimus, theophylline, warfarin).

  • Health Canada enforces a tightened acceptance interval: The $90%$ confidence interval for the geometric mean ratio (Test / Reference) of BOTH $\text{AUC}{0-t}$ and $C{\text{max}}$ must fall entirely within $90.00% \text{ to } 112.00%$ ($0.9000 - 1.1200$).

• Study Design Elements:

  • Standard design is a randomized, single-dose, two-period, two-sequence crossover ($2 \times 2$) study conducted in healthy adult human volunteers.
  • Washout Period: Must be a minimum of $5 \text{ elimination half-lives}$ ($5 \times t_{1/2}$) of the active drug and any active metabolites to guarantee complete systemic clearance before the crossover sequence.
  • Fasted vs. Fed Studies: Required under both fasting and high-fat fed conditions for modified-release formulations and immediate-release drugs known to exhibit substantial food effects.

---

3. The Biopharmaceutics Classification System (BCS)

The BCS is a scientific framework developed by Amidon et al. and standardized by Health Canada and the International Council for Harmonisation (ICH M9 Guideline). It classifies active pharmaceutical ingredients based on their aqueous solubility and intestinal permeability.

+-------------------------------------------------------------------------------------+
|                     BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS)                    |
+-------------------------------------------------------------------------------------+
|                                 AQUEOUS SOLUBILITY                                  |
|                      HIGH                                   LOW                     |
|        +-----------------------------------+-----------------------------------+    |
|   H    |           CLASS I                 |           CLASS II                |    |
|   I    | High Solubility, High Permeability| Low Solubility, High Permeability |    |
|   G    | - Rapid dissolution & absorption  | - Dissolution-rate limited        |    |
|   H    | - Candidate for Biowaiver         | - High food effect (lipids help)  |    |
| P      | - E.g., Metoprolol, Acetaminophen | - E.g., Ibuprofen, Carbamazepine  |    |
| E      +-----------------------------------+-----------------------------------+    |
| R    L |           CLASS III               |           CLASS IV                |    |
| M    O | High Solubility, Low Permeability | Low Solubility, Low Permeability  |    |
|      W | - Permeability-rate limited       | - Formulation & absorption poorly |    |
|        | - Strict Biowaiver criteria       |   predictable; low bioavailability|    |
|        | - E.g., Atenolol, Cimetidine      | - E.g., Furosemide, Paclitaxel    |    |
|        +-----------------------------------+-----------------------------------+    |
+-------------------------------------------------------------------------------------+

Regulatory Definitions of Solubility and Permeability

• High Solubility (Health Canada / ICH M9): The highest single therapeutic dose of an immediate-release dosage form dissolves completely in $\le 250\text{ mL}$ of aqueous media across the entire physiological pH range of $\text{pH } 1.2 \text{ to } 6.8$ at $37 \pm 1^\circ\text{C}$.
• High Permeability: An extent of systemic absorption in humans $\ge 85%$ of an administered dose based on mass balance determinations or in comparison to an intravenous reference dose.

Detailed Breakdown of BCS Classes

---

4. BCS-Based Biowaivers and In Vitro Dissolution Standards

A biowaiver permits the approval of an in vivo bioequivalence study exemption for an immediate-release solid oral generic formulation based on surrogate in vitro dissolution testing.

Regulatory Criteria for Biowaivers (ICH M9 / Health Canada)

1. BCS Class I Substances:
   • Active pharmaceutical ingredient meets high solubility and high permeability criteria.
   • Very Rapid Dissolution: $\ge 85%$ of the labeled active drug dissolves within $15\text{ minutes}$, or
   • Rapid Dissolution: $\ge 85%$ of the labeled active drug dissolves within $30\text{ minutes}$ using USP Apparatus I (basket at $100\text{ rpm}$) or Apparatus II (paddle at $50\text{ rpm}$) across three distinct buffer media:
     • pH 1.2 (0.1 N HCl or simulated gastric fluid without enzymes)
     • pH 4.5 (acetate buffer)
     • pH 6.8 (phosphate buffer or simulated intestinal fluid without enzymes)
   • Excipients must be standard, conventional, and qualitatively/quantitatively similar to the reference.
2. BCS Class III Substances:
   • High solubility and low permeability.
   • Must exhibit very rapid dissolution ($\ge 85%$ in $15\text{ minutes}$) across all three physiological buffers.
   • Strict Excipient Restrictions: Generic and reference products must be qualitatively identical and quantitatively very similar in excipient composition, as excipients can drastically alter intestinal transit time or membrane transporters.
3. Ineligible Drugs: Biowaivers are never granted for Critical Dose Drugs (Narrow Therapeutic Index drugs) or orally disintegrating / sublingual tablets intended for buccal absorption.

---

5. Food Effects and Excipient Interactions

Co-administration of drugs with food can drastically alter oral bioavailability through physiological and physicochemical mechanisms.

+-------------------------------------------------------------------------------------+
|                     MECHANISMS OF FOOD-DRUG INTERACTIONS                            |
+-------------------------------------------------------------------------------------+
|  Physiological Changes:                                                             |
|  - Delayed Gastric Emptying    : Increases Tmax; delays onset of action             |
|  - Splanchnic Blood Flow Surge : Decreases first-pass extraction (propranolol)      |
|  - Bile Salt Secretion         : Enhances micellar solubilization of Class II drugs |
|  - Gastric Acid Secretion      : Lowers pH (enhances ketoconazole/atazanavir)       |
|                                                                                     |
|  Physicochemical Interactions:                                                      |
|  - Polyvalent Cation Chelation : Ca2+, Mg2+, Fe2+, Al3+ bind tetracyclines/quinolones|
|  - Meal Viscosity & Binding    : Dietary fibers bind digoxin and levothyroxine      |
+-------------------------------------------------------------------------------------+

• Bile Micellar Solubilization: High-fat meals stimulate cholecystokinin release, triggering gallbladder contraction. Bile acids (taurocholic acid) and lecithin form mixed micelles that solubilize poorly water-soluble lipophilic drugs (BCS Class II, such as isotretinoin, griseofulvin, ziprasidone, vemurafenib), markedly increasing their oral bioavailability.
• Chelation Interactions: Polyvalent cations ($ ext{Ca}^{2+}$, $ ext{Mg}^{2+}$, $ ext{Al}^{3+}$, $ ext{Fe}^{2+}$, $ ext{Zn}^{2+}$) in dairy products, antacids, or mineral supplements form insoluble, non-absorbable coordination complexes with fluoroquinolones (ciprofloxacin, levofloxacin), tetracyclines (doxycycline, minocycline), and bisphosphonates (alendronate, risedronate), reducing systemic exposure by up to $80-99%$.
• Empty-Stomach Mandates: Bisphosphonates must be taken after an overnight fast with a full glass of plain water, remaining upright and fasting for $\ge 30-60\text{ minutes}$ to avoid complete loss of systemic absorption and chemical esophagitis.